WRN helicase is a synthetic lethal target in microsatellite unstable cancers.

Apoptosis / genetics CRISPR-Cas Systems / genetics Cell Cycle Checkpoints / genetics Cell Line, Tumor DNA Breaks, Double-Stranded Humans Microsatellite Instability Microsatellite Repeats / genetics Models, Genetic Neoplasms / genetics RNA Interference Synthetic Lethal Mutations / genetics Tumor Suppressor Protein p53 / metabolism Werner Syndrome Helicase / deficiency

Journal

Nature
ISSN: 1476-4687
Titre abrégé: Nature
Pays: England
ID NLM: 0410462

Informations de publication

Date de publication:
04 2019
Historique:
received: 07 08 2018
accepted: 27 02 2019
pubmed: 12 4 2019
medline: 18 12 2019
entrez: 12 4 2019
Statut: ppublish

Résumé

Synthetic lethality-an interaction between two genetic events through which the co-occurrence of these two genetic events leads to cell death, but each event alone does not-can be exploited for cancer therapeutics

Identifiants

DOI: 10.1038/s41586-019-1102-x PMID: 30971823 PMC: PMC6580861
pubmed: 30971823
doi: 10.1038/s41586-019-1102-x
pii: 10.1038/s41586-019-1102-x
pmc: PMC6580861
mid: NIHMS1522798
doi:

Substances chimiques

TP53 protein, human 0
Tumor Suppressor Protein p53 0
WRN protein, human EC 3.6.4.12
Werner Syndrome Helicase EC 3.6.4.12

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

551-556

Subventions

Organisme : NCI NIH HHS
ID : K08 CA198002
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA014236
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK034854
Pays : United States
Organisme : NCI NIH HHS
ID : T32 CA009172
Pays : United States

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Références

Chan, D. A. & Giaccia, A. J. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat. Rev. Drug Discov. 10, 351–364 (2011).
pubmed: 21532565 pmcid: 3652585
Ivy, S. P., de Bono, J. & Kohn, E. C. The ‘Pushmi–Pullyu’ of DNA repair: clinical synthetic lethality. Trends Cancer 2, 646–656 (2016).
pubmed: 28741503 pmcid: 5527674
Brown, J. S., Kaye, S. B. & Yap, T. A. PARP inhibitors: the race is on. Br. J. Cancer 114, 713–715 (2016).
pubmed: 27022824 pmcid: 4984871
Kim, T. M., Laird, P. W. & Park, P. J. The landscape of microsatellite instability in colorectal and endometrial cancer genomes. Cell 155, 858–868 (2013).
pubmed: 24209623
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature 513, 202–209 (2014).
Kunitomi, H. et al. New use of microsatellite instability analysis in endometrial cancer. Oncol. Lett. 14, 3297–3301 (2017).
pubmed: 28927079 pmcid: 5587995
Pal, T., Permuth-Wey, J., Kumar, A. & Sellers, T. A. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin. Cancer Res. 14, 6847–6854 (2008).
pubmed: 18980979 pmcid: 2655731
Le, D. T. et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science 357, 409–413 (2017).
pubmed: 28596308 pmcid: 5576142
Overman, M. J. et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J. Clin. Oncol. 36, 773–779 (2018).
pubmed: 29355075
Meyers, R. M. et al. Computational correction of copy number effect improves specificity of CRISPR–Cas9 essentiality screens in cancer cells. Nat. Genet. 49, 1779–1784 (2017).
pubmed: 29083409 pmcid: 29083409
McDonald, E. R. III et al. Project DRIVE: a compendium of cancer dependencies and synthetic lethal relationships uncovered by large-scale, deep RNAi screening. Cell 170, 577–592 (2017).
Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603–607 (2012).
pubmed: 3320027 pmcid: 3320027
Iorio, F. et al. A landscape of pharmacogenomic interactions in cancer. Cell 166, 740–754 (2016).
pubmed: 27397505 pmcid: 27397505
Swanson, C., Saintigny, Y., Emond, M. J. & Monnat, R. J. Jr. The Werner syndrome protein has separable recombination and survival functions. DNA Repair 3, 475–482 (2004).
pubmed: 15084309
Rossi, M. L., Ghosh, A. K. & Bohr, V. A. Roles of Werner syndrome protein in protection of genome integrity. DNA Repair 9, 331–344 (2010).
pubmed: 20075015 pmcid: 2827637
Buehler, E., Chen, Y. C. & Martin, S. C911: a bench-level control for sequence specific siRNA off-target effects. PLoS ONE 7, e51942 (2012).
pubmed: 23251657 pmcid: 3522603
Loughery, J., Cox, M., Smith, L. M. & Meek, D. W. Critical role for p53-serine 15 phosphorylation in stimulating transactivation at p53-responsive promoters. Nucleic Acids Res. 42, 7666–7680 (2014).
pubmed: 24928858 pmcid: 4081099
Shiloh, Y. & Ziv, Y. The ATM protein kinase: regulating the cellular response to genotoxic stress, and more. Nat. Rev. Mol. Cell Biol. 14, 197–210 (2013).
pubmed: 23847781
Nowsheen, S. & Yang, E. S. The intersection between DNA damage response and cell death pathways. Exp. Oncol. 34, 243–254 (2012).
pubmed: 23070009 pmcid: 3754840
Bendtsen, K. M. et al. Dynamics of the DNA repair proteins WRN and BLM in the nucleoplasm and nucleoli. Eur. Biophys. J. 43, 509–516 (2014).
pubmed: 25119658 pmcid: 5576897
Billingsley, C. C. et al. Polymerase ɛ (POLE) mutations in endometrial cancer: clinical outcomes and implications for Lynch syndrome testing. Cancer 121, 386–394 (2015).
pubmed: 25224212
Haugen, A. C. et al. Genetic instability caused by loss of MutS homologue 3 in human colorectal cancer. Cancer Res. 68, 8465–8472 (2008).
pubmed: 18922920 pmcid: 18922920
Sidorova, J. M. Roles of the Werner syndrome RecQ helicase in DNA replication. DNA Repair 7, 1776–1786 (2008).
pubmed: 18722555 pmcid: 2659608
Spies, M. & Fishel, R. Mismatch repair during homologous and homeologous recombination. Cold Spring Harb. Perspect. Biol. 7, a022657 (2015).
pubmed: 25731766 pmcid: 4355274
Opresko, P. L., Sowd, G. & Wang, H. The Werner syndrome helicase/exonuclease processes mobile D-loops through branch migration and degradation. PLoS ONE 4, e4825 (2009).
pubmed: 19283071 pmcid: 19283071
Myung, K., Datta, A., Chen, C. & Kolodner, R. D. SGS1, the Saccharomyces cerevisiae homologue of BLM and WRN, suppresses genome instability and homeologous recombination. Nat. Genet. 27, 113–116 (2001).
pubmed: 11138010 pmcid: 11138010
Aggarwal, M., Banerjee, T., Sommers, J. A. & Brosh, R. M. Jr. Targeting an Achilles’ heel of cancer with a WRN helicase inhibitor. Cell Cycle 12, 3329–3335 (2013).
pubmed: 24036544 pmcid: 3885643
Lebel, M. & Monnat, R. J. Jr. Werner syndrome (WRN) gene variants and their association with altered function and age-associated diseases. Ageing Res. Rev. 41, 82–97 (2018).
pubmed: 29146545
Behan, F. M. et al. Prioritization of cancer therapeutic targets using CRISPR–Cas9 screens. Nature https://doi.org/10.1038/s41586-019-1103-9 (2019).
pubmed: 30971826
Tsherniak, A. et al. Defining a cancer dependency map. Cell 170, 564–576 (2017).
pubmed: 28753430 pmcid: 28753430
Broad DepMap. DepMap Achilles 18Q4 public. FigShare version 2 https://figshare.com/articles/DepMap_Achilles_18Q4_public/7270880 (2018).
McFarland, J. M. et al. Improved estimation of cancer dependencies from large-scale RNAi screens using model-based normalization and data integration. Nat. Commun. 9, 4610 (2018).
pubmed: 30389920 pmcid: 6214982
Cancer Data Science. DEMETER2 data. FigShare version 5 https://figshare.com/articles/DEMETER2_data/6025238/5 (2018).
Cancer Cell Line Encyclopedia Consortium. Pharmacogenomic agreement between two cancer cell line data sets. Nature 528, 84–87 (2015).
Giacomelli, A. O. et al. Mutational processes shape the landscape of TP53 mutations in human cancer. Nat. Genet. 50, 1381–1387 (2018).
pubmed: 30224644 pmcid: 6168352
Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 43, e47 (2015).
pubmed: 25605792 pmcid: 25605792
Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289–300 (1995).
Robinson, M. D. & Oshlack, A. A scaling normalization method for differential expression analysis of RNA-seq data. Genome Biol. 11, R25 (2010).
pubmed: 20196867 pmcid: 2864565
Robinson, M. D., McCarthy, D. J. & Smyth, G. K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics 26, 139–140 (2010).
Law, C. W., Chen, Y., Shi, W. & Smyth, G. K. voom: precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol. 15, R29 (2014).
pubmed: 24485249 pmcid: 24485249
Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl Acad. Sci. USA 102, 15545–15550 (2005).
doi: 10.1073/pnas.0506580102
Sergushichev, A. A. An algorithm for fast preranked gene set enrichment analysis using cumulative statistic calculation. Preprint at https://www.biorxiv.org/content/10.1101/060012v1 (2016).
Liberzon, A., et al. The molecular signatures database hallmark gene set collection. Cell Syst. 1, 417–425 (2015).
pubmed: 26771021 pmcid: 4707969
Boj, S. F. et al. Organoid models of human and mouse ductal pancreatic cancer. Cell 160, 324–338 (2015).
pubmed: 25557080
Shibue, T., Brooks, M. W., Inan, M. F., Reinhardt, F. & Weinberg, R. A. The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. Cancer Discov. 2, 706–721 (2012).
pubmed: 22609699 pmcid: 3418422
Lenth, R. V. Least-squares means: the R package Ismeans. J. Stat. Softw. 69, 1–33 (2016).
Dejmek, J., Iglehart, J. D. & Lazaro, J. B. DNA-dependent protein kinase (DNA-PK)-dependent cisplatin-induced loss of nucleolar facilitator of chromatin transcription (FACT) and regulation of cisplatin sensitivity by DNA-PK and FACT. Mol. Cancer Res. 7, 581–591 (2009).
pubmed: 19372586
Bates, D. et al. Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67, 1–48 (2015).
Nagel, Z. D. et al. Multiplexed DNA repair assays for multiple lesions and multiple doses via transcription inhibition and transcriptional mutagenesis. Proc. Natl Acad. Sci. USA 111, E1823–E1832 (2014).
pubmed: 24757057
Cancer Data Science. DepMap Datasets for WRN manuscript. FigShare https://figshare.com/articles/DepMap_Datasets_for_WRN_manuscript/7712756 (2019).

Auteurs

Edmond M Chan (EM)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Tsukasa Shibue (T)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

James M McFarland (JM)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Benjamin Gaeta (B)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Mahmoud Ghandi (M)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Nancy Dumont (N)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Alfredo Gonzalez (A)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Justine S McPartlan (JS)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Tianxia Li (T)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Yanxi Zhang (Y)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Jie Bin Liu (J)

Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Jean-Bernard Lazaro (JB)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Peili Gu (P)

Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.

Cortt G Piett (CG)

Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.

Annie Apffel (A)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Syed O Ali (SO)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Rebecca Deasy (R)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Paula Keskula (P)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Raymond W S Ng (RWS)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Emma A Roberts (EA)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Elizaveta Reznichenko (E)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Lisa Leung (L)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Maria Alimova (M)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Monica Schenone (M)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Mirazul Islam (M)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Yosef E Maruvka (YE)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Yang Liu (Y)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Jatin Roper (J)

Department of Medicine, Division of Gastroenterology, Duke University, Durham, NC, USA.

Srivatsan Raghavan (S)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Marios Giannakis (M)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Yuen-Yi Tseng (YY)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Zachary D Nagel (ZD)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Environmental Health, Harvard T. H. Chan School of Public Health, Boston, MA, USA.

Alan D'Andrea (A)

Department of Radiation Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

David E Root (DE)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Jesse S Boehm (JS)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Gad Getz (G)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Massachusetts General Hospital Cancer Center, Boston, MA, USA.

Sandy Chang (S)

Department of Laboratory Medicine, Yale University School of Medicine, New Haven, CT, USA.
Department of Pathology, Yale University School of Medicine, New Haven, CT, USA.
Department of Molecular Biophysics and Biochemistry, Yale University School of Medicine, New Haven, CT, USA.

Todd R Golub (TR)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.
Department of Pediatric Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Howard Hughes Medical Institute, Chevy Chase, MD, USA.

Aviad Tsherniak (A)

Broad Institute of Harvard and MIT, Cambridge, MA, USA.

Francisca Vazquez (F)

Broad Institute of Harvard and MIT, Cambridge, MA, USA. vazquez@broadinstitute.org.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. vazquez@broadinstitute.org.

Adam J Bass (AJ)

Broad Institute of Harvard and MIT, Cambridge, MA, USA. adam_bass@dfci.harvard.edu.
Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. adam_bass@dfci.harvard.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes physiologiques cellulaires › Mort cellulaire › Mort cellulaire régulée › Apoptose › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Systèmes CRISPR-Cas › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Cycle cellulaire › Points de contrôle du cycle cellulaire › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Altération de l'ADN › Cassures de l'ADN › Cassures double-brin de l'ADN › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Instabilité du génome › Instabilité des microsatellites › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Séquences répétées en tandem › Répétitions microsatellites › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Techniques d'investigation › Modèles théoriques › Modèles biologiques › Modèles génétiques › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Tumeurs › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Épigenèse génétique › Extinction de l'expression des gènes › Interférence par ARN › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutations synthétiques létales › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Phosphoprotéines › Protéine p53 suppresseur de tumeur › WRN helicase is a synthetic lethal target in...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéines liant le poly-adp-ribose › Werner syndrome helicase › WRN helicase is a synthetic lethal target in...